Tadalafil linked to increased glaucoma risk
Analysis based on 22 articles · First reported Aug 04, 2026 · Last updated Sep 07, 2026
The study may raise safety concerns for tadalafil, potentially affecting prescribing patterns and patient monitoring, but the absolute risk increase is small and the drug remains widely used. Eli Lilly, the manufacturer of Tadalafil, may face increased scrutiny, though no regulatory action is imminent.
A large observational study published in the British Journal of Ophthalmology found that men taking tadalafil (Tadalafil) for lower urinary tract symptoms associated with benign prostatic hyperplasia had a 22% higher risk of developing glaucoma over five years compared to non-users. The study, led by researchers at National Taiwan University Hospital, analyzed health records of nearly 74,000 men aged 40 and older from the TriNetX database. It also found a 32% higher risk of ocular hypertension and a 33% higher risk of primary open-angle glaucoma. The association appeared even after one month of use. The authors emphasized that the findings do not prove causation and that patients should not stop taking the medication, but recommended baseline eye exams and monitoring, especially for those with risk factors. The study adds to previous concerns about PDE5 inhibitors and eye health.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard